Summary & Overview
CPT 83037: Point-of-Care HgbA1c Rapid Test
CPT code 83037 designates a rapid, point-of-care measurement of glycosylated hemoglobin (HgbA1c) performed on a fingerstick or venous blood specimen using an FDA-approved home-use device. This code captures a widely used clinical test that provides a three- to four-month view of glucose control, supporting diabetes diagnosis, monitoring, and treatment decisions across ambulatory and home settings. Nationally, point-of-care HgbA1c testing affects care workflows, device procurement, and payer coverage policies because results are available at the time of patient encounter and can influence immediate clinical decisions.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication covers how payers commonly handle coverage and billing for device-based point-of-care HgbA1c testing, typical service sites, and the clinical context for use.
Readers will find a concise explanation of the service represented by the code, guidance on typical sites of service, and an overview of what to expect in terms of benchmarks and policy considerations. The piece also outlines common modifiers used with laboratory and point-of-care services where Data not available in the input prevents payer-specific pricing or utilization benchmarks. The content is intended for clinicians, billing professionals, and policy analysts seeking a national overview of CPT code 83037 and its clinical role in diabetes management.
Billing Code Overview
CPT code 83037 describes a rapid point-of-care test that measures glycosylated hemoglobin (HgbA1c) using a drop of blood obtained by fingerstick or venipuncture. The test is performed by an analyst using a device that the U.S. Food and Drug Administration has approved for home use, and reports HgbA1c as a percentage of total hemoglobin, reflecting average glucose control over a three- to four-month period.
Service Type: Point-of-care HgbA1c testing (rapid, device-based)
Typical Site of Service: Clinic, outpatient office, point-of-care settings, or patient home using an FDA-approved home-use device
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with type 2 diabetes mellitus presents to a primary care clinic for routine follow-up. The clinician orders a point-of-care hemoglobin A1c test using an FDA-cleared, home-use-capable device. A trained medical assistant obtains a fingerstick specimen, runs the 83037 test on the clinic’s CLIA-waived analyzer, and documents the result as a percentage of total hemoglobin. The result is reviewed during the visit to assess glycemic control over the prior 3–4 months and to guide medication adjustments and counseling. Typical workflow includes patient check-in, brief verification of diabetes history and medications, fingerstick collection, analyzer testing (single-use cartridge or cassette), recording of the numeric A1c percent in the medical record, clinician review, and incorporation into the visit note.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management (E/M) service by the same physician on the same day | Use when an E/M visit is provided and the 83037 test is performed and documented during that visit as separate from the E/M work. |